Product Information
BIKTARVY 50-200-25 MG TABLET is a brand product labeled by Gilead Sciences, Inc., priced at $136.7284 per EA under NDC 61958250101. Its NADAC has been published 437 times since May 23, 2018.
FDA first approved this application on Feb 7, 2018.
BIKTARVY 50-200-25 MG TABLET
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarateStrength
50; 200; 25 mg/1; mg/1; mg/1
Manufacturer
Gilead Sciences, Inc.NDC
61958250101
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATEApproval Type
New Drug (NDA)
FDA Application
NDA210251FDA Approved
2/7/2018
On Market Since
2/7/2018
Pharmacological Classes
Price Statistics
The NADAC for BIKTARVY 50-200-25 MG TABLET has been published 437 times since May 23, 2018, and over the history we have for it it has risen 44.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $136.7284 per EA |
|---|---|
| All-time high | $136.7462 (Aug 12, 2026) |
| All-time low | $94.7278 (May 23, 2018) |
| 52-week high | $136.7462 |
| 52-week low | $136.6999 |
| Median price | $115.6252 |
| Average price | $116.7898 |
| Largest weekly change | +5.9% (Jan 15, 2025) |
| Weeks tracked | 437 |
| Tracking since | May 23, 2018 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Gilead Sciences, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BIKTARVY 50-200-25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BIKTARVY 50-200-25 MG TABLET, manufactured by Gilead Sciences, Inc., is $136.7284 per EA (NDC 61958250101), effective Sep 30, 2026.
How has the price of BIKTARVY 50-200-25 MG TABLET changed over time?
Over the history we have for it, the NADAC for BIKTARVY 50-200-25 MG TABLET has risen 44.3%. It has been tracked across 437 weekly CMS publications since May 23, 2018.
What are the highest and lowest recorded NADAC prices for BIKTARVY 50-200-25 MG TABLET?
Since May 23, 2018, the NADAC for BIKTARVY 50-200-25 MG TABLET has ranged from a low of $94.7278 (May 23, 2018) to a high of $136.7462 (Aug 12, 2026), with a median of $115.6252 per EA.
Are there cheaper alternatives to BIKTARVY 50-200-25 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as BIKTARVY 50-200-25 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures BIKTARVY 50-200-25 MG TABLET?
BIKTARVY 50-200-25 MG TABLET (NDC 61958250101) is labeled by Gilead Sciences, Inc., and CMS classifies it as a brand product.